Valeant Is In Trouble

Discussion in 'Valeant Pharmaceuticals' started by Anonymous, Nov 19, 2014 at 5:16 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Vicki Bryan of Gimme Credit said the often nasty battle for Allergan has exposed questions about Valeant's business model that could haunt efforts to land future large deals.

    "The problematic part of their story persists and the main thrust of their highly touted business strategy to buy their way to victory continues to lose credibility," she said in an interview.

    The corporate bond analyst criticizes Valeant's "very opaque numbers" which hide its real organic growth. It's the same complaint levelled by Allergan, which accused Valeant of relying on more than 100 acquisitions since 2008 to fuel its growth and by using price increases to camouflage what it claimed were weak increases in organic sales.

    Valeant has called those allegations "baseless."

    In addition to concerns about the quality of Valeant's core operating trends, Bryan said Valeant faces lawsuits and regulator probes on alleged insider trading in Allergan.
     

  2. Anonymous

    Anonymous Guest

    A lot of smoke and mirrors here folks. The Allergan deal destroyed Valeant. Debt is through the roof. Reality setting in. Best of luck Pearson!!!!
     
  3. Anonymous

    Anonymous Guest

    Allergan deal has pulled the curtain back on Wizard of Oz ("pay no attention to the man behind the curtain"). Valeant has been left exposed for what it is... a financial race aimed at buying companies fast enough to cover the fact that they don't care about running any of the companies they have bought.

    When stock price is more important then product... its only a matter of time before things all go wrong.
     
  4. Anonymous

    Anonymous Guest

    It sure is! They have even trolls making sure all negative comments are answered by senseless comments
     
  5. Anonymous

    Anonymous Guest

    Those positive trolls are the worst !
     
  6. Anonymous

    Anonymous Guest

    Haha.... Bring on the trolls !
     
  7. Anonymous

    Anonymous Guest

    I'll give the Ship Valeant 12 months or maybe it'll get hit by an iceberg sooner
     
  8. Anonymous

    Anonymous Guest

    Valeant hasn't made any big acquisition for over a year. They need to buy something of decent size to keep up the accounting tricks. The next few quarters' results will be very interesting. Meanwhile to stay alive the company will have to do the corporate equivalent of drinking your own piss and cut whatever that costs money.
     
  9. Anonymous

    Anonymous Guest

    Going long on Valeant now ?
    The usual dire predictions from the Allergan trolls was next quarter.
     
  10. Anonymous

    Anonymous Guest

    My take is that in three years, there will be no Valeant. It will have simply imploded.
     
  11. Anonymous

    Anonymous Guest

    Maybe Pfizer or Astra Zeneca will buy Valeant before the implosion. I hear all the big pharma players are dying to get their hands on that revolutionary new Valeant treatment, Onexton Gel.
     
  12. Anonymous

    Anonymous Guest

    I heard Valeant was buying Ireland for just the address. Any truth to the rumor Mike?
     
  13. Anonymous

    Anonymous Guest

    Yeah done that already. There will be cost savings of €14 Billion & I'll keep the "best of the best " on the island. Hehehe. D'ya think that would work to save us?
     
  14. Anonymous

    Anonymous Guest

    Oh yeah baby... Hehehe. We're sunk
     
  15. Anonymous

    Anonymous Guest

    If you really believed that you wouldn't be here.
     
  16. Anonymous

    Anonymous Guest

    Just riding the gravy train like everyone is asshole
     
  17. Anonymous

    Anonymous Guest

    Hello, and good evening. As you may all know, we have come off a bruising and demoralizing year after our failed though honest attempt at a lowball takeover of Allergan. But now we move on, with the wind of our recent PR announcements on $2 billion in potential stock buybacks, FDA-approval on yet another iteration of clindamycin/benzoyl peroxide acne treatment , and a 6% patient success rate for our new blockbuster drug Jublia firmly filling our sails... or our sales... or whatever...

    Thank you for your continued trust in our management team, and good luck out there on the trail as our most valued "Valeant Road Warriors".

    And by the way, speaking about that road, just to remind everyone: We are a Canadian pharmaceutical company, and Canadian Thanksgiving was actually celebrated last month. Thanksgiving is over. So get that snow shovel out of your garage, and start digging a path for your company car to hit the road again, a path to our common future prosperity, starting early tomorrow. Looking forward to Q4 2014 results,
     
  18. Anonymous

    Anonymous Guest

    Too funny
     
  19. Anonymous

    Anonymous Guest

    $106 million in severance is not R&D investment!!!!!!!!!
     
  20. Anonymous

    Anonymous Guest

    this is what Valeant means by "organic" growth. Not only are cutting costs by giving us fewer samples, but they hold the samples as long as possible. #CookTheBooks